Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study

[1]  Yuwon Kim,et al.  Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study , 2022, Journal of Cancer Research and Clinical Oncology.

[2]  S. Culine,et al.  Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. , 2021, Clinical genitourinary cancer.

[3]  K. Aben,et al.  Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population‐based study from 1993 to 2017 , 2021, BJU international.

[4]  F. Saad,et al.  Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. , 2020, European urology oncology.

[5]  Steven L. Chang,et al.  Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. , 2020, European urology.

[6]  J. Donovan,et al.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial , 2020, The Lancet.

[7]  V. Margulis,et al.  Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. , 2019, The Journal of urology.

[8]  K. Awai,et al.  Clinical staging of upper urinary tract urothelial carcinoma for T staging: Review and pictorial essay , 2019, International journal of urology : official journal of the Japanese Urological Association.

[9]  D. Canes,et al.  An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database , 2018, Clinical genitourinary cancer.

[10]  M. Babjuk,et al.  Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) , 2017, World Journal of Urology.

[11]  Steven L. Chang,et al.  Upper tract urothelial carcinoma: a different disease entity in terms of management , 2016, ESMO Open.

[12]  A. Horváth,et al.  Why are upper tract urothelial carcinoma two different diseases? , 2016, Translational andrology and urology.

[13]  C. Edelstein,et al.  Pathophysiology of Cisplatin-Induced Acute Kidney Injury , 2014, BioMed research international.

[14]  O. Cussenot,et al.  The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). , 2013, Urologic oncology.

[15]  M. Stifelman,et al.  Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. , 2010, European urology.

[16]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[17]  Z. Dong,et al.  Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. , 2008, Kidney international.

[18]  K. Pummer,et al.  Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. , 2008, European urology.

[19]  K. Nugent,et al.  Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.

[20]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[21]  Ishtiaq Rehman,et al.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.